CRISPR Therapeutics (Germany) Today
| 1CG Stock | 40.80 0.00 0.00% |
Performance0 of 100
| Odds Of DistressOver 67
|
CRISPR Therapeutics is selling for under 40.80 as of the 8th of January 2025; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 40.8. CRISPR Therapeutics has more than 67 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 19th of January 2023 and ending today, the 8th of January 2025. Click here to learn more.
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
CRISPR Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. CRISPR Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding CRISPR Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | ISP (View all Themes) |
| Business Concentration | ISP (View all Sectors) |
CRISPR Therapeutics AG (1CG) is traded on Stuttgart Exchange in Germany . The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.99 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CRISPR Therapeutics's market, we take the total number of its shares issued and multiply it by CRISPR Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
CRISPR Therapeutics generates negative cash flow from operations
Check CRISPR Therapeutics Probability Of Bankruptcy
CRISPR Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
Additional Tools for CRISPR Stock Analysis
When running CRISPR Therapeutics' price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.